- Coordinator
- Fondazione Ebris, Italy
- Runs
- 1 December 2022 to 31 May 2027
- Status
- Running
- EU funding
- €10.0m
- Total cost
- €10.0m
- Partners
- 14 organisations in 10 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101095436
What the project is doing
In the project's own words, from its summary on CORDIS.
280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depre280M of people worldwide suffers from major depressive disorders (MDD). Although a well- populated therapeutic landscape of anti-depressants, the number of patients in remission is particularly low with not more than 6% of the patients who benefit from the current therapeutic journey. OPADE objective is to identify key biomarkers that support the decision-making process of the healthcare providers.
The project focuses on the microbiota – brain -axis which plays a major role in mental health and in particular MDD. Through clinical investigations, the consortium partners will study the combination between genetics, epigenetics, microbiome and inflammatory networks to:-Establish patient profiles to predict and optimise the efficacy of the antidepressants prescribed with an increase in the remission rate and reduction of impairment of real-life functioning,-Establish the possible correlation between neuroinflammatory indices, target indicators of the microbiome, metabolomics, immune-profile linked, epigenomic, enzymatic algorithms,-Evaluate molecular and non-molecular biomarkers that may represent predictive indices of recurrence-Discover new molecular targets for a personalised approach,-Improve the diagnostic accuracy for primary prevention,-Evaluate retrospectively, using accurate anamnesis, the onset of depressive symptoms in adolescence.-Establish how much and to what extent do blood biomarkers correlate with other specific biomarkers350 patients between 14 and 50 years will be recruited in 4 EU and international countries for 24 months.
Real-time EEG and patient cognitive assessment will be collected with blood, stool and saliva samples. Results and analysis will be used to train the AI / ML predictive tool, the main outcome of the project. A patient empowerment tool will be deployed over the project duration.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fondazione Ebris | Salerno | Italy | Coordinator |
| Perseus Biomics | Tienen | Belgium | Participant |
| Fundacion Universitaria Sanitas | Bogota | CO | Participant |
| Mama Health Technologies GmbH | Potsdam | Germany | Participant |
| Protobios Ou | Tallinn | Estonia | Participant |
| Biokeralty Research Institute Aie | Vitoria-Gasteiz | Spain | Participant |
| Fundacio Eurecat | Cerdanyola Del Valles (Barcelona) | Spain | Participant |
| Fundacio Institut D'investigacio Biomedica De Girona Doctor Josep Trueta | Girona | Spain | Participant |
| Cephalgo | Strasbourg | France | Participant |
| Ceinge Biotecnologie Avanzate Franco Salvatore Scarl | Napoli | Italy | Participant |
| Universita Degli Studi Di Siena | Siena | Italy | Participant |
| Stichting Universitaire En Algemene Kinder - En Jeugdpsychiatrie Noord-Nederland | Assen | Netherlands | Participant |
| Artificial Intelligence Expert SRL | Cluj Napoca | Romania | Participant |
| Istanbul Medipol Universitesi | Istanbul | Türkiye | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI